课题基金 / 基金详情

Congenital CMV and CNS Infection Mechanisms of Protective Immunity

Congenital CMV and CNS Infection Mechanisms of Protective Immunity
先天性巨细胞病毒和中枢神经系统感染的保护性免疫机制
批准号:
8450754
负责人:
William Jarvis Britt
金额:
$52.21万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-05-13 至 2016-04-30

项目摘要

项目成果

William Jarvis Britt的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):先天性人巨细胞病毒(HCMV)是发育中的胎儿获得的最常见的病毒感染。虽然大多数在子宫内感染的婴儿不会出现长期症状,但大约10%的婴儿会有长期的后遗症。中枢神经系统(CNS)损伤是这些长期后遗症的唯一原因。预防中枢神经系统感染和疾病是目前抗病毒治疗的目标,已被提出作为预防性疫苗的目标。先天性感染人类婴儿的中枢神经系统疾病的发病机制尚不清楚,迄今为止,在HCMV感染中枢神经系统的动物模型中进行的研究几乎没有提供任何信息,这是由于这些模型固有的显著局限性。我们最近开发了一种小鼠CMV感染发育中的中枢神经系统的模型,该模型概括了人类疾病的许多关键特征,包括在一些动物中进行性听力损失。利用这个模型,我们建议定义限制中枢神经系统感染和疾病的保护性抗体的机制。此外,我们将探索使用工程化病毒,减少其引起中枢神经系统疾病的能力,并建立持续感染,以诱导保护性抗体反应。我们预计这些研究将确定开发靶向生物制剂(如抗体和减毒复制病毒)的策略,这些生物制剂可以提供免疫介导的保护,防止先天性HCMV感染后的中枢神经系统感染和损伤。由于MCMV和HCMV之间的相关性,这些策略可以迅速转化为人类使用的类似生物制剂的开发。
英文摘要
DESCRIPTION (provided by applicant): Congenital human cytomegalovirus (HCMV) represents the most common viral infection acquired by the developing fetus. Although most infants infected in-utero do not suffer long term symptoms, approximately 10% can have long term sequelae. Central nervous system (CNS) damage is the singular cause of these long term sequelae. Prevention of CNS infection and disease is the target of current antiviral treatment and has been proposed as a goal of prophylactic vaccines. The pathogenesis of CNS disease in congenitally infected human infants remains undefined and to date studies in animal models of CNS infection by HCMV have provided little information secondary to significant limitations inherent in these models. We have recently developed a murine model of infection of the developing CNS with the related murine CMV that recapitulates many key characteristics of the human disease, including hearing loss that is progressive in some animals. Using this model we propose to define mechanisms of protective antibodies that limit CNS infection and disease. In addition, we will explore the use of engineered viruses that are attenuated in their capacity to cause CNS disease and establish persistent infection to induce protective antibody responses. We anticipate that these studies will identify strategies for development of targeted biologics such as antibodies and attenuated replicating viruses that can provide immunologically mediated protection from CNS infection and damage that can follow congenital HCMV infection. Because of the relatedness between MCMV and HCMV, these strategies could be rapidly transitioned into development of similar biologics for human use.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tegument Envelope Protein Interactions in CMV Envelopment
CMV Vaccines: Reinfection and Antigenic Variation
CMV Vaccines: Reinfection and Antigenic Variation
CMV Vaccines: Reinfection and Antigenic Variation
海外基金